|
gptkbp:instanceOf
|
gptkb:drug
antipsychotic medication
phenothiazine derivative
|
|
gptkbp:approvalYear
|
1956
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:ATCCode
|
N05AB04
|
|
gptkbp:brand
|
gptkb:Compazine
gptkb:Stemetil
|
|
gptkbp:CASNumber
|
58-38-8
|
|
gptkbp:category
|
antiemetic
typical antipsychotic
|
|
gptkbp:contraindication
|
hypersensitivity to phenothiazines
|
|
gptkbp:discoveredIn
|
1956
|
|
gptkbp:eliminationHalfLife
|
4-8 hours
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:hasMolecularFormula
|
C20H24ClN3S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Prochlorperazine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
dopamine D2 receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
4771
DB00433
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
rectal
|
|
gptkbp:sideEffect
|
constipation
dizziness
drowsiness
dry mouth
extrapyramidal symptoms
|
|
gptkbp:UNII
|
O7M5YNV5GF
|
|
gptkbp:usedFor
|
nausea
schizophrenia
vomiting
anxiety
|
|
gptkbp:bfsParent
|
gptkb:Antiemetics
|
|
gptkbp:bfsLayer
|
6
|